MxA mRNA expression as a biomarker of interferon beta response in multiple sclerosis patients
Abstract Myxovirus resistance protein A (MxA) is a molecule induced after interferon-β injection. The aim of this study was to investigate whether MxA determination one year after starting interferon-β can predict treatment response in multiple sclerosis patients. MxA mRNA expression was evaluated i...
Gespeichert in:
Veröffentlicht in: | Journal of neuroimmunology 2016-02, Vol.291, p.73-77 |
---|---|
Hauptverfasser: | , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 77 |
---|---|
container_issue | |
container_start_page | 73 |
container_title | Journal of neuroimmunology |
container_volume | 291 |
creator | Matas, Elisabet Bau, Laura Martínez-Iniesta, María Romero-Pinel, Lucía Mañé-Martínez, M. Alba Cobo-Calvo, Álvaro Martínez-Yélamos, Sergio |
description | Abstract Myxovirus resistance protein A (MxA) is a molecule induced after interferon-β injection. The aim of this study was to investigate whether MxA determination one year after starting interferon-β can predict treatment response in multiple sclerosis patients. MxA mRNA expression was evaluated in blood samples obtained at baseline and at month 12. Clinical variables were prospectively recorded. A threshold of 5 was defined to establish MxA induction. On survival analysis, time to the next relapse and to EDSS progression were significantly longer in patients showing MxA induction, suggesting that MxA induction after one year may be useful to identify interferon-β responders. |
doi_str_mv | 10.1016/j.jneuroim.2015.12.015 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1768576457</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0165572815301089</els_id><sourcerecordid>1764338991</sourcerecordid><originalsourceid>FETCH-LOGICAL-c456t-4313311ed8318ef1bb6c7591d04f3ba3ee342686cfd46ec88e8b2cb6c1ba05183</originalsourceid><addsrcrecordid>eNqNkstu1TAQhi0EoqcHXqHykk1ST-wkzgZxVJWLVIrUwhJZjjORnOaGJ0Ht29fRaVmwgdUs5vvn8s8wdgYiBQHFeZd2I65h8kOaCchTyNIYXrAd6DJLtMrgJdtFME_yMtMn7JSoE5GQqnrNTrJC56Wq9I79_Hp_4MPN9YHj_RyQyE8jt8Qtr_002HCHgU8t9-OCocUQkzUulkdynkbCmODD2i9-7pGT6yNBnvhsF4_jQm_Yq9b2hG-f4p79-Hj5_eJzcvXt05eLw1XiVF4siZIgJQA2WoLGFuq6cGVeQSNUK2srEaWKIxeubVSBTmvUdeYiBLUVOWi5Z--Odecw_VqRFjN4ctj3dsRpJQPltnCh8vJ_UCWlriqIaHFEXdyKArZmDj568mBAmO0KpjPPVzDbFQxkZvN4z86eeqz1gM0f2bPtEfhwBDCa8ttjMOSiYQ4bH9Atppn8v3u8_6uE6_3one3v8AGpm9YwRssNGIoCc7v9wvYKUSpA6Eo-AoffsaY</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1764338991</pqid></control><display><type>article</type><title>MxA mRNA expression as a biomarker of interferon beta response in multiple sclerosis patients</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Matas, Elisabet ; Bau, Laura ; Martínez-Iniesta, María ; Romero-Pinel, Lucía ; Mañé-Martínez, M. Alba ; Cobo-Calvo, Álvaro ; Martínez-Yélamos, Sergio</creator><creatorcontrib>Matas, Elisabet ; Bau, Laura ; Martínez-Iniesta, María ; Romero-Pinel, Lucía ; Mañé-Martínez, M. Alba ; Cobo-Calvo, Álvaro ; Martínez-Yélamos, Sergio</creatorcontrib><description>Abstract Myxovirus resistance protein A (MxA) is a molecule induced after interferon-β injection. The aim of this study was to investigate whether MxA determination one year after starting interferon-β can predict treatment response in multiple sclerosis patients. MxA mRNA expression was evaluated in blood samples obtained at baseline and at month 12. Clinical variables were prospectively recorded. A threshold of 5 was defined to establish MxA induction. On survival analysis, time to the next relapse and to EDSS progression were significantly longer in patients showing MxA induction, suggesting that MxA induction after one year may be useful to identify interferon-β responders.</description><identifier>ISSN: 0165-5728</identifier><identifier>EISSN: 1872-8421</identifier><identifier>DOI: 10.1016/j.jneuroim.2015.12.015</identifier><identifier>PMID: 26857498</identifier><language>eng</language><publisher>Netherlands: Elsevier B.V</publisher><subject>Adult ; Allergy and Immunology ; Basic Helix-Loop-Helix Leucine Zipper Transcription Factors - genetics ; Basic Helix-Loop-Helix Leucine Zipper Transcription Factors - metabolism ; Biomarker ; Biomarkers - blood ; Cohort Studies ; Disability Evaluation ; Female ; Gene Expression Regulation - drug effects ; Humans ; Immunologic Factors - therapeutic use ; Interferon-beta ; Interferon-beta - therapeutic use ; Male ; Middle Aged ; Multiple sclerosis ; Multiple Sclerosis - drug therapy ; Multiple Sclerosis - metabolism ; Multiple Sclerosis - mortality ; MxA ; Neurology ; Prospective Studies ; RNA, Messenger - metabolism ; Statistics, Nonparametric ; Survival Analysis ; Treatment response</subject><ispartof>Journal of neuroimmunology, 2016-02, Vol.291, p.73-77</ispartof><rights>Elsevier B.V.</rights><rights>2016 Elsevier B.V.</rights><rights>Copyright © 2016 Elsevier B.V. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c456t-4313311ed8318ef1bb6c7591d04f3ba3ee342686cfd46ec88e8b2cb6c1ba05183</citedby><cites>FETCH-LOGICAL-c456t-4313311ed8318ef1bb6c7591d04f3ba3ee342686cfd46ec88e8b2cb6c1ba05183</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.jneuroim.2015.12.015$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,777,781,3537,27905,27906,45976</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26857498$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Matas, Elisabet</creatorcontrib><creatorcontrib>Bau, Laura</creatorcontrib><creatorcontrib>Martínez-Iniesta, María</creatorcontrib><creatorcontrib>Romero-Pinel, Lucía</creatorcontrib><creatorcontrib>Mañé-Martínez, M. Alba</creatorcontrib><creatorcontrib>Cobo-Calvo, Álvaro</creatorcontrib><creatorcontrib>Martínez-Yélamos, Sergio</creatorcontrib><title>MxA mRNA expression as a biomarker of interferon beta response in multiple sclerosis patients</title><title>Journal of neuroimmunology</title><addtitle>J Neuroimmunol</addtitle><description>Abstract Myxovirus resistance protein A (MxA) is a molecule induced after interferon-β injection. The aim of this study was to investigate whether MxA determination one year after starting interferon-β can predict treatment response in multiple sclerosis patients. MxA mRNA expression was evaluated in blood samples obtained at baseline and at month 12. Clinical variables were prospectively recorded. A threshold of 5 was defined to establish MxA induction. On survival analysis, time to the next relapse and to EDSS progression were significantly longer in patients showing MxA induction, suggesting that MxA induction after one year may be useful to identify interferon-β responders.</description><subject>Adult</subject><subject>Allergy and Immunology</subject><subject>Basic Helix-Loop-Helix Leucine Zipper Transcription Factors - genetics</subject><subject>Basic Helix-Loop-Helix Leucine Zipper Transcription Factors - metabolism</subject><subject>Biomarker</subject><subject>Biomarkers - blood</subject><subject>Cohort Studies</subject><subject>Disability Evaluation</subject><subject>Female</subject><subject>Gene Expression Regulation - drug effects</subject><subject>Humans</subject><subject>Immunologic Factors - therapeutic use</subject><subject>Interferon-beta</subject><subject>Interferon-beta - therapeutic use</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Multiple sclerosis</subject><subject>Multiple Sclerosis - drug therapy</subject><subject>Multiple Sclerosis - metabolism</subject><subject>Multiple Sclerosis - mortality</subject><subject>MxA</subject><subject>Neurology</subject><subject>Prospective Studies</subject><subject>RNA, Messenger - metabolism</subject><subject>Statistics, Nonparametric</subject><subject>Survival Analysis</subject><subject>Treatment response</subject><issn>0165-5728</issn><issn>1872-8421</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkstu1TAQhi0EoqcHXqHykk1ST-wkzgZxVJWLVIrUwhJZjjORnOaGJ0Ht29fRaVmwgdUs5vvn8s8wdgYiBQHFeZd2I65h8kOaCchTyNIYXrAd6DJLtMrgJdtFME_yMtMn7JSoE5GQqnrNTrJC56Wq9I79_Hp_4MPN9YHj_RyQyE8jt8Qtr_002HCHgU8t9-OCocUQkzUulkdynkbCmODD2i9-7pGT6yNBnvhsF4_jQm_Yq9b2hG-f4p79-Hj5_eJzcvXt05eLw1XiVF4siZIgJQA2WoLGFuq6cGVeQSNUK2srEaWKIxeubVSBTmvUdeYiBLUVOWi5Z--Odecw_VqRFjN4ctj3dsRpJQPltnCh8vJ_UCWlriqIaHFEXdyKArZmDj568mBAmO0KpjPPVzDbFQxkZvN4z86eeqz1gM0f2bPtEfhwBDCa8ttjMOSiYQ4bH9Atppn8v3u8_6uE6_3one3v8AGpm9YwRssNGIoCc7v9wvYKUSpA6Eo-AoffsaY</recordid><startdate>20160215</startdate><enddate>20160215</enddate><creator>Matas, Elisabet</creator><creator>Bau, Laura</creator><creator>Martínez-Iniesta, María</creator><creator>Romero-Pinel, Lucía</creator><creator>Mañé-Martínez, M. Alba</creator><creator>Cobo-Calvo, Álvaro</creator><creator>Martínez-Yélamos, Sergio</creator><general>Elsevier B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>7T5</scope><scope>7TK</scope><scope>H94</scope></search><sort><creationdate>20160215</creationdate><title>MxA mRNA expression as a biomarker of interferon beta response in multiple sclerosis patients</title><author>Matas, Elisabet ; Bau, Laura ; Martínez-Iniesta, María ; Romero-Pinel, Lucía ; Mañé-Martínez, M. Alba ; Cobo-Calvo, Álvaro ; Martínez-Yélamos, Sergio</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c456t-4313311ed8318ef1bb6c7591d04f3ba3ee342686cfd46ec88e8b2cb6c1ba05183</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Adult</topic><topic>Allergy and Immunology</topic><topic>Basic Helix-Loop-Helix Leucine Zipper Transcription Factors - genetics</topic><topic>Basic Helix-Loop-Helix Leucine Zipper Transcription Factors - metabolism</topic><topic>Biomarker</topic><topic>Biomarkers - blood</topic><topic>Cohort Studies</topic><topic>Disability Evaluation</topic><topic>Female</topic><topic>Gene Expression Regulation - drug effects</topic><topic>Humans</topic><topic>Immunologic Factors - therapeutic use</topic><topic>Interferon-beta</topic><topic>Interferon-beta - therapeutic use</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Multiple sclerosis</topic><topic>Multiple Sclerosis - drug therapy</topic><topic>Multiple Sclerosis - metabolism</topic><topic>Multiple Sclerosis - mortality</topic><topic>MxA</topic><topic>Neurology</topic><topic>Prospective Studies</topic><topic>RNA, Messenger - metabolism</topic><topic>Statistics, Nonparametric</topic><topic>Survival Analysis</topic><topic>Treatment response</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Matas, Elisabet</creatorcontrib><creatorcontrib>Bau, Laura</creatorcontrib><creatorcontrib>Martínez-Iniesta, María</creatorcontrib><creatorcontrib>Romero-Pinel, Lucía</creatorcontrib><creatorcontrib>Mañé-Martínez, M. Alba</creatorcontrib><creatorcontrib>Cobo-Calvo, Álvaro</creatorcontrib><creatorcontrib>Martínez-Yélamos, Sergio</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>Immunology Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><jtitle>Journal of neuroimmunology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Matas, Elisabet</au><au>Bau, Laura</au><au>Martínez-Iniesta, María</au><au>Romero-Pinel, Lucía</au><au>Mañé-Martínez, M. Alba</au><au>Cobo-Calvo, Álvaro</au><au>Martínez-Yélamos, Sergio</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>MxA mRNA expression as a biomarker of interferon beta response in multiple sclerosis patients</atitle><jtitle>Journal of neuroimmunology</jtitle><addtitle>J Neuroimmunol</addtitle><date>2016-02-15</date><risdate>2016</risdate><volume>291</volume><spage>73</spage><epage>77</epage><pages>73-77</pages><issn>0165-5728</issn><eissn>1872-8421</eissn><abstract>Abstract Myxovirus resistance protein A (MxA) is a molecule induced after interferon-β injection. The aim of this study was to investigate whether MxA determination one year after starting interferon-β can predict treatment response in multiple sclerosis patients. MxA mRNA expression was evaluated in blood samples obtained at baseline and at month 12. Clinical variables were prospectively recorded. A threshold of 5 was defined to establish MxA induction. On survival analysis, time to the next relapse and to EDSS progression were significantly longer in patients showing MxA induction, suggesting that MxA induction after one year may be useful to identify interferon-β responders.</abstract><cop>Netherlands</cop><pub>Elsevier B.V</pub><pmid>26857498</pmid><doi>10.1016/j.jneuroim.2015.12.015</doi><tpages>5</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0165-5728 |
ispartof | Journal of neuroimmunology, 2016-02, Vol.291, p.73-77 |
issn | 0165-5728 1872-8421 |
language | eng |
recordid | cdi_proquest_miscellaneous_1768576457 |
source | MEDLINE; Elsevier ScienceDirect Journals |
subjects | Adult Allergy and Immunology Basic Helix-Loop-Helix Leucine Zipper Transcription Factors - genetics Basic Helix-Loop-Helix Leucine Zipper Transcription Factors - metabolism Biomarker Biomarkers - blood Cohort Studies Disability Evaluation Female Gene Expression Regulation - drug effects Humans Immunologic Factors - therapeutic use Interferon-beta Interferon-beta - therapeutic use Male Middle Aged Multiple sclerosis Multiple Sclerosis - drug therapy Multiple Sclerosis - metabolism Multiple Sclerosis - mortality MxA Neurology Prospective Studies RNA, Messenger - metabolism Statistics, Nonparametric Survival Analysis Treatment response |
title | MxA mRNA expression as a biomarker of interferon beta response in multiple sclerosis patients |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-20T14%3A14%3A53IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=MxA%20mRNA%20expression%20as%20a%20biomarker%20of%20interferon%20beta%20response%20in%20multiple%20sclerosis%20patients&rft.jtitle=Journal%20of%20neuroimmunology&rft.au=Matas,%20Elisabet&rft.date=2016-02-15&rft.volume=291&rft.spage=73&rft.epage=77&rft.pages=73-77&rft.issn=0165-5728&rft.eissn=1872-8421&rft_id=info:doi/10.1016/j.jneuroim.2015.12.015&rft_dat=%3Cproquest_cross%3E1764338991%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1764338991&rft_id=info:pmid/26857498&rft_els_id=S0165572815301089&rfr_iscdi=true |